Clck to enlarge and view details
US PROVISIONAL PATENT APPLICATIONS IN BLOOD ANTICLOT TECHNOLOGY PUBLISHED IN 2012
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included drugs, medications, formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors,
heparin, warfarin and related technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve and select highly
relevant documents.

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

US PATENT APPLICATIONS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED IN 2012



Application No.: US20120000299A1  Published: 05/Jan/2012

Title: Method and device for providing blood constituents

Applicant/Assignee: ROCHE DIAGNOSTICS OPERATIONS, INC

Application No.: 13/206830   Filing Date: 10/Aug/2011

Abstract:

A metering capillary and method for providing at least one defined volume of a target constituent of a sample is provided, the method comprising providing at least one metering capillary having at least two openings

at least partly filling the metering capillary with the sample

carrying out a constituent separation for the at least partial separation of at least two constituents of the sample inside the metering capillary

and dividing the metering capillary into at least two partial pieces, wherein at least one of the partial pieces contains the defined volume of the target constituent.

Priority: EP20090152982 Applic. Date: 2009-02-17; WO2010EP00908 Applic. Date: 2010-02-15

Inventor: BUECHNER KARL-HEINZ [DE]


Application No.: US20120003315A1  Published: 05/Jan/2012

Title: Flowable Carrier Matrix

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 13/233100   Filing Date: 15/Sep/2011

Abstract:

A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenetic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2010-977310 Applic. Date: 2010-12-23; US2009-634323 Applic. Date: 2009-12-09; US2006-504363 Applic. Date: 2006-08-14

Inventor: BEALS NEIL [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]


Application No.: US20120003730A1  Published: 05/Jan/2012

Title: PORTABLE SAMPLE ANALYZER CARTRIDGE

Applicant/Assignee: HONEYWELL INTERNATIONAL INC

Application No.: 13/220449   Filing Date: 29/Aug/2011

Abstract:

A sample analyzer cartridge for use at a point of care of a patient such as in a doctor's office, in the home, or elsewhere in the field. By providing a removable and/or disposable cartridge with all of the needed reagents and/or fluids, the sample analyzer can be reliably used outside of the laboratory environment, with little or no specialized training.

Priority: US2005-908460 Applic. Date: 2005-05-12; US2004-571235P Applic. Date: 2004-05-14

Inventor: PADMANABHAN ARAVIND [US]; COX JAMES A [US]; CABUZ CLEOPATRA [US]


Application No.: US20120004499A1  Published: 05/Jan/2012

Title: Surgical Method for Performing a Coronary Blood Vessel Bypass

Applicant/Assignee: LEXION MEDICAL, LLC

Application No.: 12/829072   Filing Date: 01/Jul/2010

Abstract:

In accordance with one embodiment of the present disclosure, a surgical method may include making a first incision in a patient. The surgical method may also include receiving a gas from a source and humidifying and warming the gas received from the source. The surgical method may further include delivering the humidified and warmed gas into the first incision. The surgical method may further include separating one or more blood vessel branches from a blood vessel using at least one surgical instrument inserted through a second incision in the patient. The surgical method may further include removing a blood vessel segment from the patient through a third incision in the patient, wherein the blood vessel segment was in contact with the humidified and warmed gas delivered into the first incision prior to the removal.

Priority:

Inventor: OTT DOUGLAS E [US]


Application No.: US20120004524A1  Published: 05/Jan/2012

Title: PROTRUDENT ANALYTE SENSOR

Applicant/Assignee: MEDTRONIC MINIMED, INC

Application No.: 13/233338   Filing Date: 15/Sep/2011

Abstract:

The methods and apparatus for detecting an analyte in blood are useful for detecting an analyte in tissue of a subject. The apparatus comprises a sensor, which comprises an elongated conductive material having a protrudent end, the protrudent end comprising an electrode that detects the presence of an analyte

a substrate affixed to the conductive material

and a support having an external surface, a proximal end, and a distal end. The conductive material is positioned on the support and the protrudent end of the conductive material protrudes beyond the distal end of the support. Optionally, the sensor is suspended within the lumen of a venous flow device. Typically, only a portion of the sensor is suspended within the lumen of the venous flow device, said portion comprising the protrudent end of the conductive material. Alternatively, the conductive material is positioned on the external surface of the intravenous infusion catheter.

Priority: US2006-348894 Applic. Date: 2006-02-07; US2004-935954 Applic. Date: 2004-09-08

Inventor: VAN ANTWERP NANNETTE M [US]; HOSS UDO [US]


Application No.: US20120020948A1  Published: 26/Jan/2012

Title: DAG-TYPE AND INDIRECT PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE

Applicant/Assignee:

Application No.: 13/178821   Filing Date: 08/Jul/2011

Abstract:

The present disclosure provides a method for treating stroke by administering an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator, wherein the PKC activator may be administered before, after, or at the same time as the rTPA. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone

and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are compositions and kits comprising rTPA and a PKC activator for treating stroke.

Priority: US2010-362464P Applic. Date: 2010-07-08; US2010-412753P Applic. Date: 2010-11-11; US2010-412747P Applic. Date: 2010-11-11

Inventor: ALKON DANIEL L [US]


Application No.: US20120027687A1  Published: 02/Feb/2012

Title: FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE

Applicant/Assignee:

Application No.: 13/178835   Filing Date: 08/Jul/2011

Abstract:

The present disclosure provides a method for treating stroke by administering an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C(PKC) activator, wherein the PKC activator may be administered before, after, or at the same time as the rTPA. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone

and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are compositions and kits comprising rTPA and a PKC activator for treating stroke.

Priority: US2010-362464P Applic. Date: 2010-07-08; US2010-412753P Applic. Date: 2010-11-11; US2010-412747P Applic. Date: 2010-11-11

Inventor: ALKON DANIEL L [US]


Application No.: US20120028236A1  Published: 02/Feb/2012

Title: COMPOSITION FOR PRESERVING PLATELETS AND METHOS OF USE THEREOF

Applicant/Assignee: BIOVEC TRANSFUSION, LLC

Application No.: 13/180389   Filing Date: 11/Jul/2011

Abstract:

A platelet preservation composition is disclosed. The composition comprises a photosensitizer, an inhibitor of platelet activation, and/or an anticoagulant. The preservation composition allows inactivation of pathogens in a platelet preparation while maintaining the functionality of the platelets.

Priority: US2010-368078P Applic. Date: 2010-07-27

Inventor: SEHGAL LAKSHMAN R [US]


Application No.: US20120028881A1  Published: 02/Feb/2012

Title: METHODS AND REAGENTS FOR DIAGNOSING ATHEROMA

Applicant/Assignee: IMPERIAL INNOVATIONS LIMITED

Application No.: 13/132828   Filing Date: 03/Dec/2009

Abstract:

The invention provides a method of diagnosing atheroma in an individual, the method comprising providing a sample from the individual, determining the level of lysozyme in the sample and assessing whether the level is indicative of atheroma in the individual. The invention also provides the use of a reagent which selectively identifies lysozyme in the assessment of atheroma in an individual.

Priority: GB20080022140 Applic. Date: 2008-12-04; WO2009GB02821 Applic. Date: 2009-12-03

Inventor: WILKINS MARTIN R [GB]; EDWARDS ROBERT JOHN [GB]


Application No.: US20120029372A1  Published: 02/Feb/2012

Title: Drug Delivery Methods and Systems

Applicant/Assignee: GREATBATCH LTD

Application No.: 13/271717   Filing Date: 12/Oct/2011

Abstract:

Drug delivery methods and systems that include a determination of whether a cardiac condition is normal or abnormal, so that a drug may be administered in accordance with that determination. In one implementation, a drug delivery device may be controlled to reduce or stop the drug administration when a normal cardiac condition is detected. In another implementation, a patient monitoring device determines the duration that a cardiac condition is normal and provides an output indicative of the determination so that the patient may alter a therapy accordingly.

Priority: US2008-165328 Applic. Date: 2008-06-30

Inventor: HAEFNER PAUL A [US]; MOON LOELL BOYCE [US]


Application No.: US20120031773A1  Published: 09/Feb/2012

Title: IMMUNOASSAY METHOD AND DEVICE WITH MAGNETICALLY SUSCEPTIBLE BEAD CAPTURE

Applicant/Assignee: ABBOTT POINT OF CARE

Application No.: 13/204109   Filing Date: 05/Aug/2011

Abstract:

The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.

Priority: US2010-371066P Applic. Date: 2010-08-05

Inventor: MILLER CARY JAMES [CA]


Application No.: US20120032095A1  Published: 09/Feb/2012

Title: METHOD AND APPARATUS FOR DETECTING PHARMACEUTICALS IN A SAMPLE

Applicant/Assignee:

Application No.: 13/263399   Filing Date: 25/Mar/2010

Abstract:

A method and apparatus for measuring a vitamin K antagonizing anticoagulant present in a sample (116), arranged to: irradiate (304) the sample (116) with light from a light source (114) for exciting the anticoagulant through its absorption of the light, the excitation of the sample (116) resulting in a fluorescent emission from the sample (116)

measure (306) the fluorescent emission from the sample (116)

determine (308) a fluorescence lifetime ([tau]1) of the fluorescent emission of the sample (116)

determine (310) an intensity (A1) of the fluorescent emission at the fluorescence lifetime ([tau]1)

and determine (312) a amount (c) of the anticoagulant, as a function of the intensity (A1) of the fluorescent emission at the fluorescence lifetime ([tau]1).

Priority: SE20090050225 Applic. Date: 2009-04-07; WO2010SE50326 Applic. Date: 2010-03-25

Inventor: NICHOLLS IAN A [SE]; KARLSSON BJORN C G [SE]; ROSENGREN ANNIKA M [SE]; ANDERSSON PER OLA [SE]


Application No.: US20120034205A1  Published: 09/Feb/2012

Title: PKC ACTIVATORS AND ANTICOAGULANT IN REGIMEN FOR TREATING STROKE

Applicant/Assignee:

Application No.: 13/178843   Filing Date: 08/Jul/2011

Abstract:

The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone

and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke.

Priority: US2010-362464P Applic. Date: 2010-07-08; US2010-412753P Applic. Date: 2010-11-11; US2010-412747P Applic. Date: 2010-11-11

Inventor: ALKON DANIEL L [US]


Application No.: US20120034624A1  Published: 09/Feb/2012

Title: OSCILLATING IMMUNOASSAY METHOD AND DEVICE

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 13/204172   Filing Date: 05/Aug/2011

Abstract:

The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.

Priority: US2010-371085P Applic. Date: 2010-08-05

Inventor: MILLER CARY JAMES [CA]; CAMPBELL JOHN LEWIS EMERSON [CA]


Application No.: US20120034633A1  Published: 09/Feb/2012

Title: MAGNETIC IMMUNOSENSOR AND METHOD OF USE

Applicant/Assignee: ABBOTT POINT OF CARE

Application No.: 13/204121   Filing Date: 05/Aug/2011

Abstract:

The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.

Priority: US2010-371109P Applic. Date: 2010-08-05

Inventor: MILLER CARY JAMES [CA]; HU JINGHUA [CA]


Application No.: US20120034684A1  Published: 09/Feb/2012

Title: MAGNETIC IMMUNOSENSOR WITH TRENCH CONFIGURATION AND METHOD OF USE

Applicant/Assignee: ABBOTT POINT OF CARE

Application No.: 13/204094   Filing Date: 05/Aug/2011

Abstract:

The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.

Priority: US2010-371077P Applic. Date: 2010-08-05

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; MILLER CARY JAMES [CA]


Application No.: US20120035450A1  Published: 09/Feb/2012

Title: BLOOD COAGULATION SYSTEM ANALYZER, AND BLOOD COAGULATION SYSTEM ANALYSIS METHOD AND PROGRAM

Applicant/Assignee: SONG CORPORATION

Application No.: 13/142991   Filing Date: 07/Jan/2010

Abstract:

A blood coagulation system analysis device capable of analyzing a blood coagulation system with high accuracy, and a method and a program for analysis of a blood coagulation system are proposed. The blood coagulation system is observed as a temporal change in permittivity before the viscoelasticity manifestation timing (timing at which blood starts to clot from the viewpoint of viscoelasticity (in greater detail, timing at which active polymerization of fibrin monomers starts)). A permittivity of blood which is positioned between a pair of electrodes is measured at predetermined time intervals after the anticoagulant effect acting on the blood is ended, and from the measurement result, a degree of the action of the blood coagulation system is analyzed.

Priority: JP20090002650 Applic. Date: 2009-01-08; JP20090293156 Applic. Date: 2009-12-24; WO2010JP50367 Applic. Date: 2010-01-07

Inventor: HAYASHI YOSHIHITO [JP]


Application No.: US20120039884A1  Published: 16/Feb/2012

Title: COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE

Applicant/Assignee: REVALESIO CORPORATION

Application No.: 13/209154   Filing Date: 12/Aug/2011

Abstract:

Provided are methods for treating cardiovascular diseases and related conditions and symptoms (e.g., cardiac arrhythmia, vascular disease, myocardial infarction, congestive heart failure, myocarditis, atherosclerosis, and restenosis), comprising administering to a subject in need thereof a therapeutically effective amount of an electrokinetically altered aqueous fluid as described herein. In particular aspects, the electrokinetically altered aqueous fluids comprise an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures predominantly having an average diameter of less than about 100 nanometers and sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity. Provided are routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions, along with use of the electrokinetically altered aqueous fluids in surgical contexts, including but not limited to cardiovascular related surgeries. Additionally provided are methods for measuring biological activity of electrokinetically altered fluids.

Priority: US2010-373494P Applic. Date: 2010-08-13; US201161485071P Applic. Date: 2011-05-11

Inventor: WATSON RICHARD L [US]; WOOD ANTHONY B [US]; ARCHAMBEAU GREGORY J [US]


Application No.: US20120045518A1  Published: 23/Feb/2012

Title: ENHANCING COAGULATION OR REDUCING FIBRINOLYSIS

Applicant/Assignee: THE UAB RESEARCH FOUNDATION

Application No.: 13/254287   Filing Date: 05/Mar/2010

Abstract:

Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma).

Priority: US2009-157719P Applic. Date: 2009-03-05; WO2010US26377 Applic. Date: 2010-03-05

Inventor: NIELSEN VANCE G [US]; GEORGE JAMES F [US]; KIRKLIN JAMES K [US]


Application No.: US20120046230A1  Published: 23/Feb/2012

Title: Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor

Applicant/Assignee: MILLENNIUM PHARMACEUTICALS, INC

Application No.: 13/213912   Filing Date: 19/Aug/2011

Abstract:

The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Priority: US2008-101644 Applic. Date: 2008-04-11; US2007-911852P Applic. Date: 2007-04-13

Inventor: SINHA UMA [US]; HOLLENBACH STANLEY J [US]; ANDRE PATRICK [US]


Application No.: US20120048751A1  Published: 01/Mar/2012

Title: MEDICAL DEVICE PACKAGE

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 13/292129   Filing Date: 09/Nov/2011

Abstract:

The present disclosure provides a package for a medical device containing a cavity for receiving the medical device, a first closure having a sealed portal therein and a second closure adjacent the first closure.

Priority: US2009-528561 Applic. Date: 2009-08-25; WO2008US02458 Applic. Date: 2008-02-26; US2007-904927P Applic. Date: 2007-03-05

Inventor: STOPEK JOSHUA B [US]; KIRSCH DAVID [US]


Application No.: US20120052562A1  Published: 01/Mar/2012

Title: TEST MODULE WITH MICROFLUIDIC DEVICE HAVING LAMINAR STRUCTURE AND SAMPLE RECEPTACLE

Applicant/Assignee: GENEASYS PTY LTD

Application No.: 13/149925   Filing Date: 01/Jun/2011

Abstract:

A test module having an outer casing for hand held portability, and, a microfluidic device for processing a biological sample mounted in the outer casing, the microfluidic device having a lab-on-a-chip (LOC) device with a cap, the LOC device having a supporting substrate and a microsystems technologies (MST) layer on the supporting substrate, the MST layer incorporating MST channels and a plurality of fluidic connections for fluid communication with the cap, and the cap having a sample inlet and cap channels for fluid communication with the fluidic connections.

Priority: US2010-356018P Applic. Date: 2010-06-17; US201161437686P Applic. Date: 2011-01-30

Inventor: SILVERBROOK KIA [AU]; AZIMI MEHDI [AU]


Application No.: US20120053501A1  Published: 01/Mar/2012

Title: METHODS AND SYSTEMS FOR ANTICOAGULATING BLOOD

Applicant/Assignee:

Application No.: 12/861974   Filing Date: 24/Aug/2010

Abstract:

Methods and systems are provided for anticoagulating blood. Whole blood is drawn from a donor into a system at a draw flow rate. Anticoagulant from an anticoagulant source is pumped into the system at an anticoagulant flow rate to mix with the blood. The anticoagulated blood may be subsequently processed in any of a number of known ways, including separating it and removing at least a portion of one of the components of the blood. Thereafter, at least a portion of the remaining blood may be returned to the donor. The anticoagulant flow rate is independent of the draw flow rate and can be based on a number of factors, including the weight of the donor and the rate at which the donor can metabolize the anticoagulant.

Priority:

Inventor: BROWN RICHARD I [US]


Application No.: US20120063953A1  Published: 15/Mar/2012

Title: MEDICAL HEAT EXCHANGER, MANUFACTORING THEREOF AND ARTIFICIAL LUNG DEVICE

Applicant/Assignee: JMS CO., LTD

Application No.: 13/321037   Filing Date: 05/Mar/2010

Abstract:

A thin tube bundle (2) including a plurality of heat transfer thin tubes (1) is sealed by seal members (3a-3c) to form a blood channel (5) that crosses the heat transfer thin tubes. Heat transfer thin tube headers (6, 7) having an inlet port and an outlet port (6a, 7a) of heat medium liquid form flow chambers that contain ends of the thin tube bundle. The thin tube bundle is divided in a direction of the blood channel and forms a stack structure of thin tube bundle units (12a-12c). The flow chambers are partitioned into a plurality of flow compartments (13a, 13b, 14a, 14b) by partition walls (6b, 7b) to form a channel that allows heat medium liquid to pass through the respective thin tube bundle units successively via the flow compartments. An end of one of the thin tube bundle units on both sides of a border corresponding to the partition wall protrudes further than an end of the other thin tube bundle unit, and a side face of the partition wall contacts an side face of the protruding portion. Thus, the flow velocity of the heat medium liquid flowing through the heat transfer thin tubes is increased, and hence, heat exchange efficiency is enhanced while suppressing the increase in volume of the blood channel.

Priority: JP20090137981 Applic. Date: 2009-06-09; WO2010JP53645 Applic. Date: 2010-03-05

Inventor: IZUMIDA HIDEKI [JP]; NIITSUMA TOMOKAZU [JP]


Application No.: US20120063996A1  Published: 15/Mar/2012

Title: NOVEL NIMESULIDE COMPOSITIONS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 13/193545   Filing Date: 28/Jul/2011

Abstract:

The present invention provides nanoparticulate nimesulide compositions. The compositions preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides methods of making and using nanoparticulate nimesulide compositions.

Priority: US2000-572961 Applic. Date: 2000-05-18; US2003-276400 Applic. Date: 2003-01-15; US2003-697703 Applic. Date: 2003-10-31

Inventor: BOSCH H WILLIAM [US]; WERTZ CHRISTIAN F [US]


Application No.: US20120064552A1  Published: 15/Mar/2012

Title: USING BLOOD CLOT IN MICROFLUIDIC VALVING APPLICATIONS

Applicant/Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY

Application No.: 13/232776   Filing Date: 14/Sep/2011

Abstract:

The present invention provides a method of forming a blood-clot microvalve by heating blood in a capillary tube of a microfluidic device. Also described are methods of modulating liquid flow in a capillary tube by forming and removing a blood-clot microvalve.

Priority: US2010-382867P Applic. Date: 2010-09-14

Inventor: TAI YU-CHONG [US]; SHI WENDIAN [US]; GUO LUKE [US]


Application No.: US20120065570A1  Published: 15/Mar/2012

Title: Disc shunt delivery with stepped needle

Applicant/Assignee:

Application No.: 13/199906   Filing Date: 12/Sep/2011

Abstract:

A solid stepped needle delivers a disc shunt bridging between muscle and a degenerated disc, drawing blood plasma from muscle into the degenerated disc to alleviate back pain and regenerate the disc. The device further includes pull lines attached to the ends of the disc shunt for withdrawing and repositioning the stepped needle during shunt delivery.

Priority: US2010-403188P Applic. Date: 2010-09-11

Inventor: YEUNG JEFFREY E [US]; YEUNG TERESA T [US]; YEUNG ANDREW [US]


Application No.: US20120070483A1  Published: 22/Mar/2012

Title: Multi-Functional Biocompatible Coatings for Intravascular Devices

Applicant/Assignee:

Application No.: 13/093090   Filing Date: 25/Apr/2011

Abstract:

A polymeric coating is adapted to substantially eliminate thrombus formation when in contact with blood. The polymeric coating includes a first polymeric layer and a second polymeric layer. Interposed between the first and second polymeric layers is a polymeric matrix layer doped with at least one of a nitric oxide donor and a nitric oxide generator. The nitric oxide donor and/or the nitric oxide generator are capable of releasing or generating NO. A bioactive agent is either immobilized to the surface of the second polymeric layer or is incorporated into the polymeric matrix layer.

Priority: US2004-924102 Applic. Date: 2004-08-23

Inventor: ZHOU ZHENGRONG [US]; MEYERHOFF MARK E [US]; REYNOLDS MELISSA M [US]


Application No.: US20120071855A1  Published: 22/Mar/2012

Title: COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR

Applicant/Assignee:

Application No.: 13/295240   Filing Date: 14/Nov/2011

Abstract:

The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.

Priority: US2009-401291 Applic. Date: 2009-03-10; US2006-552396 Applic. Date: 2006-10-24; US2005-734151P Applic. Date: 2005-11-07

Inventor: PECORA ANDREW L [US]; PRETI ROBERT A [US]


Application No.: US20120076750A1  Published: 29/Mar/2012

Title: FIBRIN BASED GLUE WITH FUNCTIONALIZED HYDROPHILIC POLYMER PROTEIN BINDING AGENT

Applicant/Assignee:

Application No.: 13/313578   Filing Date: 07/Dec/2011

Abstract:

The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided.

Priority: US2007-741333 Applic. Date: 2007-04-27

Inventor: ENYART HILLARY [US]; HOEPPNER JACY [US]; LEACH MIKE [US]; STEGER SHON [US]; SUNDARAMURTHY SONA [US]


Application No.: US20120076760A1  Published: 29/Mar/2012

Title: COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR CROSS-REFERENCE TO RELATED APPLICATIONS

Applicant/Assignee: AMORCYTE, INC

Application No.: 13/312718   Filing Date: 06/Dec/2011

Abstract:

The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.

Priority: US201113295240 Applic. Date: 2011-11-14; US2009-401291 Applic. Date: 2009-03-10; US2006-552396 Applic. Date: 2006-10-24; US2005-734151P Applic. Date: 2005-11-07

Inventor: PECORA ANDREW L [US]; PRETI ROBERT A [US]


Application No.: US20120077182A1  Published: 29/Mar/2012

Title: ADDITIVE SOLUTION FOR BLOOD PRESERVATION

Applicant/Assignee: THE TRUSTEES OF BOSTON UNIVERSITY

Application No.: 13/310289   Filing Date: 02/Dec/2011

Abstract:

A method for the storage of red blood cells provides for mixing an additive solution with packed red blood cells to create a suspension of red blood cells. The method further provides for reducing the oxygen in the suspension of red blood cells

and storing the suspension of red blood cells under oxygen-depleted storage.

Priority: US2005-128576 Applic. Date: 2005-05-13; US2002-295781 Applic. Date: 2002-11-15; US2001-332405P Applic. Date: 2001-11-16

Inventor: BITENSKY MARK W [US]; YOSHIDA TATSURO [US]


Application No.: US20120079887A1  Published: 05/Apr/2012

Title: STRAIN SENSOR ELEMENT AND BLOOD PRESSURE SENSOR

Applicant/Assignee: KABUSHIKI KAISHA TOSHIBA

Application No.: 13/110392   Filing Date: 18/May/2011

Abstract:

A strain sensor element comprises a laminated film which has a magnetic free layer, a spacer layer, and a magnetic reference layer. The free layer has a variable magnetization direction and a out-of-plane magnetization direction. The reference layer has a variable magnetization direction which is pinned more strongly than the magnetization of the free layer. The spacer layer provided between the free layer and the reference layer. A pair of electrodes is provided with a plane of the laminated film. A substrate is provided with either of the pair electrodes and can be strained. The rotation angle of the magnetization of the free layer is different from the rotation angle of the magnetization of the reference layer when the substrate is distorted. Electrical resistance is changed depending on the magnetization angle between the free layer and the reference layer, which allows the element to operate as a strain sensor.

Priority: JP20100223175 Applic. Date: 2010-09-30

Inventor: GIDDINGS ALEXANDER DEVIN [JP]; FUKUZAWA HIDEAKI [JP]; FUJI YOSHIHIKO [JP]; YUASA HIROMI [JP]; HARA MICHIKO [JP]; MURAKAMI SHUICHI [JP]


Application No.: US20120082715A1  Published: 05/Apr/2012

Title: Stabilized products, processes and devices for preparing the same

Applicant/Assignee:

Application No.: 13/199573   Filing Date: 02/Sep/2011

Abstract:

A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of perishable products, especially pharmaceutical agents, such as human blood and blood products (e.g., red blood cells). A single emulsion process comprising a 2-phase system for preserving food and pharmaceutical products is also provided. Stabilized biological products as glassified beads are also provided, as well as a method for rehydrating and/or reconstituting the glassified beads to provide useful and fully active reconstituted and/or rehydrated materials is also presented.

Priority: US2007-796451 Applic. Date: 2007-04-27; US2003-527810P Applic. Date: 2003-12-08; US2004-007104 Applic. Date: 2004-12-08; US2004-619863P Applic. Date: 2004-10-18

Inventor: NEEDHAM DAVID [US]


Application No.: US20120087955A1  Published: 12/Apr/2012

Title: NANOPARTICULATE MEGESTROL FORMULATIONS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LIMITED

Application No.: 13/269427   Filing Date: 07/Oct/2011

Abstract:

The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.

Priority: US2006-472556 Applic. Date: 2006-06-22; US2005-093149 Applic. Date: 2005-03-30; US2004-878623 Applic. Date: 2004-06-29; US2003-412669 Applic. Date: 2003-04-14; US2005-693127P Applic. Date: 2005-06-22; US2002-371680P Applic. Date: 2002-04-12; US2002-430348P Applic. Date: 2002-12-03

Inventor: HOVEY DOUGLAS [US]; PRUITT JOHN [US]; RYDE TUULA [US]


Application No.: US20120088736A1  Published: 12/Apr/2012

Title: [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 13/271037   Filing Date: 11/Oct/2011

Abstract:

The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

Priority: US2005-733650P Applic. Date: 2005-11-03; US2006-556490 Applic. Date: 2006-11-03

Inventor: SCARBOROUGH ROBERT [US]; SCARBOROUGH CARROLL ANNA CREW [US]; HUANG WOLIN [US]; MEHROTRA MUKUND [US]; ZHANG XIAOMING [US]; CANNON HILARY [GB]; GRANT CRAIG M [GB]


Application No.: US20120089116A9  Published: 12/Apr/2012

Title: DEVICES FOR DELIVERING SUBSTANCES THROUGH AN EXTRA-ANATOMIC OPENING CREATED IN AN AIRWAY

Applicant/Assignee: BRONCUS TECHNOLOGIES, INC

Application No.: 11/538950   Filing Date: 05/Oct/2006

Abstract:

Devices and methods for delivering substances to lung tissue through an extra-anatomic passage created in an airway.

Priority: US2004-895022 Applic. Date: 2004-07-19

Inventor: ROSCHAK EDMUND J [US]


Application No.: US20120093936A1  Published: 19/Apr/2012

Title: METHOD AND DEVICE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH INFLAMMATION OR UNDESIRABLE ACTIVATION OF THE IMMUNE SYSTEM

Applicant/Assignee: VELIN-PHARMA A/S

Application No.: 13/262677   Filing Date: 07/Apr/2010

Abstract:

The present invention relates to methods and compositions for use in the treatment of specific medical conditions. The compositions of the invention comprise blood serum preparations, such as activated blood serum preparations. The present invention also relates to the use of such blood serum preparations for the treatment of diseases and disorders associated with inflammation and/or undesirable activation of the immune system, such as paradentosis, abortus habitualis, colitis ulcerosa, polymyalgia rheumatica, whiplash-associated disorders, endometriosis, adeomyosis and unexplained infertility.

Priority: DK20090000471 Applic. Date: 2009-04-07; EP20090169937 Applic. Date: 2009-09-10; US2009-167333P Applic. Date: 2009-04-07; WO2010EP54590 Applic. Date: 2010-04-07

Inventor: LINDENBERG SVEND [DK]; VELIN FLEMMING [DK]


Application No.: US20120107845A1  Published: 03/May/2012

Title: Disrupting FCRN-Albumin Interactions

Applicant/Assignee: THE BRIGHAM & WOMEN'S HOSPITAL, INC, BRIGHAM & WOMEN'S HOSPITAL, INC

Application No.: 13/322983   Filing Date: 28/May/2010

Abstract:

Provided herein are, inter alia, methods for identifying a candidate compound for treating the toxic effects of compounds or molecules that bind to albumin in a subject. The methods include identifying test compounds that inhibit the binding between FcRn and albumin.

Priority: US2009-182479P Applic. Date: 2009-05-29; WO2010US36572 Applic. Date: 2010-05-28

Inventor: BLUMBERG RICHARD S [US]; KUO TIMOTHY T C [US]


Application No.: US20120108651A1  Published: 03/May/2012

Title: GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF

Applicant/Assignee: LEIDEN UNIVERSITY MEDICAL CENTER (LUMC) ACTING ONBEHALF OF ACADEMIC HOSPITAL LEIDEN (AZL), CELERA CORPORATION

Application No.: 13/286934   Filing Date: 01/Nov/2011

Abstract:

The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment (particularly for reducing the risk of venous thrombosis). For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

Priority: US2010-409434P Applic. Date: 2010-11-02

Inventor: BARE LANCE [US]; DEVLIN JAMES J [US]; ROSENDAAL FRITS R [NL]; REITSMA PIETER H [NL]; BEZEMER IRENE D [NL]


Application No.: US20120114716A1  Published: 10/May/2012

Title: Flowable Carrier Matrix

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 13/353632   Filing Date: 19/Jan/2012

Abstract:

A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenetic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2009-635289 Applic. Date: 2009-12-10; US2006-504363 Applic. Date: 2006-08-14

Inventor: BEALS NEIL B [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]


Application No.: US20120115182A1  Published: 10/May/2012

Title: MASS SPECTROMETRIC DIAGNOSIS OF SEPTICEMIA

Applicant/Assignee:

Application No.: 13/322363   Filing Date: 14/Jul/2010

Abstract:

The invention mainly relates to the mass spectrometric identification of pathogens in blood cultures from blood-stream infections (septicemia). The invention provides a method with which microbial pathogens can be separated in purified form from blood after a relatively brief cultivation in a blood culture flask, without any interfering human proteins or any residual fractions of blood particles such as erythrocytes and leukocytes, and can be directly identified by mass spectrometric measurement of their protein profiles. The method is based on the use of relatively strong tensides to destroy the blood particles by dissolving the weak cell membranes and most of the internal structures of the blood particles

in spite of the fact that tensides are regarded as strong ionization inhibitors in MALDI and other ionization processes required for mass spectrometric measurements. This method allows unknown pathogens to be obtained in their pure form by centrifuging or filtration and to be identified on the taxonomic level of species or subspecies. Problems with DNA from high levels of leukocytes can be resolved by special measures. After sufficient cultivation, the identification in a mass spectrometric laboratory takes only half an hour.

Priority: WO2010EP60098 Applic. Date: 2010-07-14; DE200910033368 Applic. Date: 2009-07-16

Inventor: MAIER THOMAS [DE]


Application No.: US20120121530A1  Published: 17/May/2012

Title: Vasoprotective and cardioprotective antidiabetic therapy

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 13/295174   Filing Date: 14/Nov/2011

Abstract:

The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Priority: EP20100191261 Applic. Date: 2010-11-15; EP20110168317 Applic. Date: 2011-05-31; EP20110170992 Applic. Date: 2011-06-22; US201161492391P Applic. Date: 2011-06-02; US2010-421400P Applic. Date: 2010-12-09; US2010-415545P Applic. Date: 2010-11-19

Inventor: KLEIN THOMAS [DE]; DAIBER ANDREAS [DE]; JOHANSEN ODD-ERIC [NO]; MARK MICHAEL [DE]; PATEL SANJAYKUMAR [GB]; WOERLE HANS-JUERGEN [DE]


Application No.: US20120121572A1  Published: 17/May/2012

Title: NEW MEDICINES FOR TOPIC USE BASED ON SULFATED HYALURONIC ACID AS ACTIVATING OR INHIBITING AGENT OF THE CYTOKINE ACTIVITY

Applicant/Assignee: FIDIA FARMACEUTICI S.P.A

Application No.: 13/320000   Filing Date: 14/May/2010

Abstract:

The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.

Priority: IT2009PD00134 Applic. Date: 2009-05-14; WO2010EP03050 Applic. Date: 2010-05-14

Inventor: D ESTE MATTEO [IT]; GENNARI GIOVANNI [IT]


Application No.: US20120123297A1  Published: 17/May/2012

Title: SYSTEMS AND INTERFACES FOR BLOOD SAMPLING

Applicant/Assignee: SEVENTH SENSE BIOSYSTEMS, INC

Application No.: 13/292254   Filing Date: 09/Nov/2011

Abstract:

The present invention generally relates to systems and methods for delivering and/or receiving a substance or substances such as blood from subjects. In one aspect, the present invention is directed to devices and methods for receiving or extracting blood from a subject, e.g., from the skin and/or from beneath the skin, using devices containing a substance transfer component (for example, one or more needles or microneedles) and a reduced pressure or vacuum chamber having an internal pressure less than atmospheric pressure prior to receiving blood. In some embodiments, the device may contain a "snap dome" or other deformable structure, which may be used, at least in part, to urge or move needles or other suitable substance transfer components into the skin of a subject. In some cases, for example, the device may contain a flexible concave member and a needle mechanically coupled to the flexible concave member.

Priority: US2010-411566P Applic. Date: 2010-11-09

Inventor: BRANCAZIO DAVID [US]


Application No.: US20120123314A1  Published: 17/May/2012

Title: CITRATE ANTICOAGULATION SYSTEM FOR EXTRACORPOREAL BLOOD TREATMENTS

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/359109   Filing Date: 26/Jan/2012

Abstract:

A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.

Priority: US2005-739086P Applic. Date: 2005-11-22; WO2000EP03583 Applic. Date: 2000-04-20; US2001-959543 Applic. Date: 2001-10-23; US2003-742137 Applic. Date: 2003-12-19; US2006-602827 Applic. Date: 2006-11-21; EP19990201302 Applic. Date: 1999-04-26

Inventor: LANNOY JEAN-MICHEL [FR]


Application No.: US20120123466A1  Published: 17/May/2012

Title: AXIALLY VARIABLE RADIAL PRESSURE CAGES FOR CLOT CAPTURE

Applicant/Assignee: STRYKER NV OPERATIONS, LTD, STRYKER CORPORATION

Application No.: 13/291749   Filing Date: 08/Nov/2011

Abstract:

A device for removing a blood clot from a lumen of a vessel, the device comprising a pusher and an expandable tubular cage fixedly engaged to the pusher. The tubular cage has a proximal end, a distal end, and a wall extending therebetween. The wall comprises a plurality of bands of cells axially arranged along the tubular cage, wherein one band of cells comprises at least one skiving cell having a cell wall with a proximal portion, a distal portion, and a central portion between the proximal portion and the distal portion. The central portion deforms radially inward in response to a radially applied force to a greater extent than the distal portion.

Priority: US2010-413174P Applic. Date: 2010-11-12

Inventor: PORTER STEPHEN C [US]; KELLETT JAMES B [US]; KJOS DEL [US]


Application No.: US20120128654A1  Published: 24/May/2012

Title: Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma

Applicant/Assignee: UNIVERSITY OF CINCINNATI

Application No.: 13/265584   Filing Date: 23/Apr/2010

Abstract:

Methods for inhibiting the progression of neurodegenerative diseases and treating neurotrauma-induced damage and cerebrovascular disease are provided herein, the methods including the administration of a safe and effective amount of allantoin to a patient in need thereof. Also provided are pharmaceutical compositions including allantoin for the inhibition of the progression of neurodegenerative diseases and for the treatment of neurotrauma-induced damage and cerebrovascular disease.

Priority: US2009-172019P Applic. Date: 2009-04-23; WO2010US32201 Applic. Date: 2010-04-23

Inventor: TERPSTRA BRIAN T [US]; SORTWELL CARYL E [US]


Application No.: US20120129148A1  Published: 24/May/2012

Title: COMPOSITIONS AND METHODS FOR THE STORAGE OF RED BLOOD CELLS

Applicant/Assignee:

Application No.: 13/354601   Filing Date: 20/Jan/2012

Abstract:

The present invention provides an aqueous composition for storage of red blood cells consisting essentially of: adenine

dextrose

at least one nonmetabolizable membrane-protectant sugar

and a specifically defined pH buffering system. Also provided are improved methods for preserving red blood cells and methods for increasing the viability, membrane retention, and recoverability while suppressing apoptosis, hemolysis, and post-reinfusion clearance of stored red blood cells which utilize the novel compositions.

Priority: US2005-060026 Applic. Date: 2005-02-17; US2004-545582P Applic. Date: 2004-02-18

Inventor: HESS JOHN R [US]; GREENWALT TIBOR J [US]


Application No.: US20120130278A1  Published: 24/May/2012

Title: DEVICE FOR EXTRACTING BLOOD FROM THE PLACENTA AND/OR UMBILICAL CORD

Applicant/Assignee:

Application No.: 13/386927   Filing Date: 14/Jul/2010

Abstract:

A device is provided to extract and collect blood from the placenta and/or umbilical cord, through a system that combines collecting the blood as it falls by the effect of gravity, together with a suction system that facilitates the fall. The device allows a greater amount of blood to be extracted than that obtained using conventional gravity methods, without entailing any risk to the mother's health, thereby allowing a controlled suction that prevents premature expulsion of the placenta.

Priority: WO2010EP60131 Applic. Date: 2010-07-14; ES20090030536 Applic. Date: 2009-07-30

Inventor: ALVAREZ RAMOS ANGEL GABRIEL [ES]


Application No.: US20120134974A1  Published: 31/May/2012

Title: METHODS FOR REMOVING PLASMA

Applicant/Assignee: BIOVEC TRANSFUSION, LLC

Application No.: 13/282006   Filing Date: 26/Oct/2011

Abstract:

A method for preparing a blood component composition for reducing risk of transfusion related injury includes passing a blood component composition through a tangential flow filter unit comprising one or more filter membranes. A diafiltration solution is added to the blood component composition during the filtration process. Non-cellular plasma components, including antibodies, are removed from the blood component composition by the tangential flow filtration.

Priority: US2010-418022P Applic. Date: 2010-11-30

Inventor: SEHGAL LAKSHMAN R [US]


Application No.: US20120135405A1  Published: 31/May/2012

Title: INSTRUMENT AND METHOD FOR OPTICAL PARTICLE SENSING

Applicant/Assignee: INVITROX, INC

Application No.: 13/322132   Filing Date: 20/May/2010

Abstract:

A new device capable of measuring the number of particles present in a colloidal suspension is disclosed, which includes a forward scatter detector, an extinction detector, a laser beam, a cylindrical lens with which to create a plane of light through which particles can pass, and the various pumps and tubing needed to pass the colloidal suspension through the plane of light. The device is particularly designed for measuring particles which have different refractive indices, and which are in the size range of between about 0.7 to 2 microns. The device can determine the presence or absence of biological particles of interest in a given sample, by incubating a sample with a given ratio of active particles and marker particles, and determining whether the ratio of active particles and marker particles has changed. Additional binding and/or non-binding particles can also be present, and kits including the particles are also disclosed.

Priority: US2009-181182P Applic. Date: 2009-05-26; WO2010US35621 Applic. Date: 2010-05-20

Inventor: TOUMBAS PAUL [US]; GABRIEL DON [US]


Application No.: US20120136582A1  Published: 31/May/2012

Title: MEASURING HEMATOCRIT AND ESTIMATING HEMOGLOBIN VALUES WITH A NON-INVASIVE, OPTICAL BLOOD MONITORING SYSTEM

Applicant/Assignee: FRESENIUS MEDICAL CARE HOLDINGS, INC

Application No.: 13/366119   Filing Date: 03/Feb/2012

Abstract:

An optical blood monitoring system with a ratiometric model determines hematocrit values for a hemodialysis patient, from which hemoglobin values for the patient are estimated. The ratiometric model is calibrated, normally against a cell counter, using blood from a blood bank. The blood from a blood bank is preserved in a long term preservative which is typically different than that found in clinical settings. The hematocrit value determined by the ratiometric model is scaled by scaling factor so that the estimated hemoglobin level output from the monitor consistently matches that measured in a clinical setting.

The hematocrit scaling factor is substantially about 1.033 when the patient's blood sample is stored in a short term preservative ethylene diamine tetra acetic, and is substantially about 1.06 when the hematocrit is measured in the blood sample without preservative being added to the blood sample. The hemoglobin value can also be adjusted for altitude.

Priority: US2008-265392 Applic. Date: 2008-11-05

Inventor: BARRETT LOUIS LEEGRANDE [US]; PETERSON DAVID WAYNE [US]; SAMMANN KRISTIAN ALLEN [US]


Application No.: US20120141337A1  Published: 07/Jun/2012

Title: FLUORESCENCE DETECTOR, FILTER DEVICE AND RELATED METHODS

Applicant/Assignee:

Application No.: 13/348495   Filing Date: 11/Jan/2012

Abstract:

A microfluidic filter is disclosed. The filter can be used with onchip fluid filtration such as whole blood filtration for microfluidic blood analysis. The filter is able to filter the necessary volume of fluid and in particular blood in an acceptable time frame.

Priority: US2007-804112 Applic. Date: 2007-05-17; US2006-802068P Applic. Date: 2006-05-19; US2007-900426P Applic. Date: 2007-02-09

Inventor: MALTEZOS GEORGE [US]; LEE JOHN KIM [US]; SCHERER AXEL [US]; KARTALOV EMIL [US]


Application No.: US20120141562A1  Published: 07/Jun/2012

Title: CELL COATED IMPLANTABLE DEVICE

Applicant/Assignee:

Application No.: 13/389891   Filing Date: 12/Aug/2010

Abstract:

The present invention relates, in general, to a cell-coated implantable medical device and, in particular, to an implantable medical device the blood-contacting surfaces of which are coated with endothelial progenitor cells (EPCs). In a preferred embodiment, the medical device is a titanium or titanium alloy-based medical device.

Priority: US2009-272054P Applic. Date: 2009-08-12; WO2010US02235 Applic. Date: 2010-08-12

Inventor: ACHNECK HARDEAN E [US]; TRUSKEY GEORGE A [US]; JAMIOLKOWSKI RYAN M [US]


Application No.: US20120141756A1  Published: 07/Jun/2012

Title: BREATHABLE INSECT PROTECTION FABRIC

Applicant/Assignee:

Application No.: 13/377601   Filing Date: 11/Jun/2010

Abstract:

Breathable mosquito-resistant fabric includes an internal layer, outer fabric layer and an intermediate layer, which allows a soft and elastic compression such as springs or an open cell foam. This fabric is suitable for the production of garments and other wearable articles, such as shoes.

Priority: IT2009PV00010 Applic. Date: 2009-06-12; WO2010IB01647 Applic. Date: 2010-06-11

Inventor: RAMAIOLI FRANCESCO [IT]


Application No.: US20120142025A1  Published: 07/Jun/2012

Title: Ratiometric Immunoassay Method and Blood Testing Device

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 13/308953   Filing Date: 01/Dec/2011

Abstract:

The invention is to devices and methods for rapid determination of analytes in liquid samples. The devices and methods incorporate a sample dilution feature and multiple immunosensors for performing a ratiometric immunoassay on a first analyte and a second analyte, for example, hemoglobin and hemoglobin A1c or albumin and glycosylated albumin. The devices are preferably capable of being used in the point-of-care diagnostic field.

Priority: US2010-419497P Applic. Date: 2010-12-03

Inventor: MILLER CARY JAMES [CA]


Application No.: US20120145583A1  Published: 14/Jun/2012

Title: Suicide bomb deterrent

Applicant/Assignee:

Application No.: 12/803783   Filing Date: 06/Jul/2010

Abstract:

One embodiment of a manufactured device presenting as a Suicide Bomb Deterrent designed to preemptively warn and deter in self-defense, and if need be to retaliate in reciprocal punishment, against a potential suicide bombing terrorist, taken to be deployed in public display either upon or near one's person, comprising a frangible retention envelope (1 of FIG. 1) into which has been inserted a mixture comprising porcine derivative (2 of FIG. 1), which envelope has thereafter been hermetically sealed and permanently affixed to a plaque (7 of FIG. 6) imbued with porcine derivative (9 of FIG. 6) and which plaque carries upon it a written warning (10 of FIG. 6) of content and operational function of said envelope and plaque presentment, with a method of construction capable of large scale adaptation to provide warning and deterrent capacity for dwellings, buildings, airframes, and motorized vehicles. Other embodiments, variations, and ramifications are described and shown herein.

Priority: US2009-270414P Applic. Date: 2009-07-07

Inventor: PRICE MARK S [US]


Application No.: US20120145619A1  Published: 14/Jun/2012

Title: INTEGRATED DISPOSABLE SET FOR AN APHERESIS SYSTEM

Applicant/Assignee: CARIDIANBCT, INC

Application No.: 13/400811   Filing Date: 21/Feb/2012

Abstract:

An integrated pre-connected apheresis disposable set for separating plasma from blood in a separation vessel and further separating the separated plasma into desired plasma proteins in a plasma separator fluidly connected to the separation vessel to receive the separated plasma.

Priority: US2009-429266 Applic. Date: 2009-04-24; US2008-088154P Applic. Date: 2008-08-12; US2008-093892P Applic. Date: 2008-09-03; US2008-097598P Applic. Date: 2008-09-17; US2008-120763P Applic. Date: 2008-12-08

Inventor: URDAHL STEVEN GAGE [US]; FELT THOMAS J [US]; CORBIN III FRANK [US]


Application No.: US20120148658A1  Published: 14/Jun/2012

Title: SOLID DRESSING FOR TREATING WOUNDED TISSUE

Applicant/Assignee:

Application No.: 13/363489   Filing Date: 01/Feb/2012

Abstract:

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cm2 of the wound facing surface of the dressing and 13.0 mg/cm2 of the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue.

Priority: US2007-882876 Applic. Date: 2007-08-06; US2006-835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]


Application No.: US20120148659A1  Published: 14/Jun/2012

Title: SOLID DRESSING FOR TREATING WOUNDED TISSUE

Applicant/Assignee:

Application No.: 13/364762   Filing Date: 02/Feb/2012

Abstract:

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.

Priority: US2007-882874 Applic. Date: 2007-08-06; US2006-835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]


Application No.: US20120150087A1  Published: 14/Jun/2012

Title: SOLID DRESSING FOR TREATING WOUNDED TISSUE

Applicant/Assignee:

Application No.: 13/364837   Filing Date: 02/Feb/2012

Abstract:

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.

Priority: US2007-882879 Applic. Date: 2007-08-06; US2006-835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]


Application No.: US20120150090A1  Published: 14/Jun/2012

Title: System and Method for Delivery of Regional Citrate Anticoagulation to Extracorporeal Blood Circuits

Applicant/Assignee: HENRY FORD HEALTH SYSTEM

Application No.: 13/372860   Filing Date: 14/Feb/2012

Abstract:

The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Priority: US2007-829261 Applic. Date: 2007-07-27; WO2007US62589 Applic. Date: 2007-02-22; US2006-775729P Applic. Date: 2006-02-22; US2006-775728P Applic. Date: 2006-02-22; US2006-790882P Applic. Date: 2006-04-11; US2006-791055P Applic. Date: 2006-04-11; US2006-845646P Applic. Date: 2006-09-19

Inventor: SZAMOSFALVI BALAZS [US]; FRINAK STANLEY [US]; YEE JERRY [US]


Application No.: US20120157397A1  Published: 21/Jun/2012

Title: TRIMETHYLAMINE-CONTAINING COMPOUNDS FOR DIAGNOSIS AND PREDICTION OF DISEASE

Applicant/Assignee:

Application No.: 13/304806   Filing Date: 28/Nov/2011

Abstract:

The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.

Priority: WO2010US36705 Applic. Date: 2010-05-28; US2009-181858P Applic. Date: 2009-05-28

Inventor: HAZEN STANLEY L [US]; WANG ZENENG [US]; LEVISON BRUCE S [US]


Application No.: US20120164150A1  Published: 28/Jun/2012

Title: Monoclonal Antibodies Against Activated Protein C

Applicant/Assignee:

Application No.: 13/306301   Filing Date: 29/Nov/2011

Abstract:

The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening for and detecting these antibodies.

Priority: US2008-257706 Applic. Date: 2008-10-24; US2007-983092P Applic. Date: 2007-10-26

Inventor: XU JUN [US]; ESMON CHARLES [US]


Application No.: US20120171254A1  Published: 05/Jul/2012

Title: Process and Apparatuses for Preparing Nanoparticle Compositions with Amphiphilic Copolymers and Their Use

Applicant/Assignee:

Application No.: 13/368888   Filing Date: 08/Feb/2012

Abstract:

This invention discloses a process for making nanoparticles of amphiphilic copolymers by flash precipitation. Nanoparticles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in a nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers. Furthermore, the resulting particles exhibit sufficient stability for post processing as desired. The invention also discloses two apparatuses for the production of nanoparticles of amphiphilic copolymers by flash precipitation.

Priority: US2003-472071 Applic. Date: 2003-10-23; WO2002US10715 Applic. Date: 2002-03-29; US2001-280433P Applic. Date: 2001-03-30

Inventor: JOHNSON BRIAN K [US]; PRUD HOMME ROBERT K [US]


Application No.: US20120174264A1  Published: 05/Jul/2012

Title: Uses of Yerba Santa

Applicant/Assignee:

Application No.: 13/414841   Filing Date: 08/Mar/2012

Abstract:

Methods of in vitro propagation of plants of the genus Eriodictyon are described, including, in particular embodiments, plants of the species E. californicum, E. trichocalyx and E. sessilifolium. Methods of producing transgenic plants of the genus Eriodictyon are also described, along with methods of producing recombinant proteins in such plants. Compositions and methods for administering recombinant proteins produced in these plants are also described.

Priority: US2009-487942 Applic. Date: 2009-06-19; US2008-074376P Applic. Date: 2008-06-20

Inventor: KOPROWSKI HILARY [US]; POGREBNYAK NATALIA [US]; GOLOVKIN MAXIM [US]


Application No.: US20120175313A1  Published: 12/Jul/2012

Title: SYSTEM AND METHOD FOR ADJUSTMENT OF BLOOD SEPARATION PROCEDURE PARAMETERS

Applicant/Assignee:

Application No.: 13/345305   Filing Date: 06/Jan/2012

Abstract:

Systems and methods are provided for automatically adjusting the operational parameters of a blood separation procedure. A blood separation device has an inlet for passing fluid thereinto and an outlet for removing fluid therefrom. A pump system is provided for moving fluid into and out of the device. In use, blood is conveyed into the device, where platelets are separated from at least a portion of the blood. A controller determines the amount of platelets in the device. Based at least in part on the amount of platelets in the device, corrective action is taken to avoid platelet aggregation in the device. The corrective action may be conveying an elevated amount of anticoagulant into the blood and/or the device and may be initiated when the determined amount of platelets approaches, meets, or exceeds a threshold predicted likelihood of platelet aggregation.

Priority: US201161432002P Applic. Date: 2011-01-12

Inventor: BARRY JR JOHN W [US]; CASE BRIAN C [US]; NGUYEN LAN T [US]


Application No.: US20120177715A1  Published: 12/Jul/2012

Title: HEPARIN COFACTOR II FRAGMENTS WITH ANTI-INFLAMMATORY AND ANTI-COAGULANT ACTIVITY

Applicant/Assignee: XIMMUNE AB

Application No.: 13/497006   Filing Date: 21/Sep/2010

Abstract:

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOS: 1 to 3, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.

Priority: WO2010GB01780 Applic. Date: 2010-09-21; GB20090016578 Applic. Date: 2009-09-22

Inventor: KALLE MARTINA [SE]; KASETTY GOPINATH [SE]; MALMSTEN NILS MARTIN [SE]; PAPAREDDY PRAVEEN [SE]; SCHMIDTCHEN ARTUR [SE]; WALSE BJOERN ULRIK [SE]


Application No.: US20120177719A1  Published: 12/Jul/2012

Title: MEDICAL DEVICE INTENDED TO COME INTO CONTACT WITH A PATIENT'S TISSUE AND RELATED MANUFACTURING METHOD

Applicant/Assignee: PEROUSE MEDICAL

Application No.: 13/316022   Filing Date: 09/Dec/2011

Abstract:

A device including a body (12) including fibers without oxidized cellulose. The body (12) also includes fibers containing oxidized cellulose.

Priority: FR20100060414 Applic. Date: 2010-12-13

Inventor: DAO VITHUY [FR]; MICHELOT ROBERT [FR]; PEROUSE ERIC [FR]


Application No.: US20120178094A1  Published: 12/Jul/2012

Title: Method for Categorizing Circulating Tumor Cells

Applicant/Assignee:

Application No.: 13/393177   Filing Date: 02/Sep/2010

Abstract:

The present invention provides method for categorizing circulating tumor cells (CTCs) using various cellular markers and revealing or non-revealing assays which provide beneficial insights for clinical staging and therapy decision making in cancer patients.

Priority: US2009-239682P Applic. Date: 2009-09-03; WO2010US47676 Applic. Date: 2010-09-02

Inventor: KUHN PETER [US]


Application No.: US20120178629A1  Published: 12/Jul/2012

Title: APPARATUS AND METHODS FOR PREPARING AN EMULSION

Applicant/Assignee:

Application No.: 13/334154   Filing Date: 22/Dec/2011

Abstract:

Disclosed herein are apparatus and methods for producing emulsions, and, in particular, for maintaining laminar flow during production of emulsions containing microsuspensions.

Priority: US201061426705P Applic. Date: 2010-12-23

Inventor: HUDSON BRUCE W [US]; OPPERMAN GARY W [US]; RAICHE ADRIAN T [US]


Application No.: US20120183519A1  Published: 19/Jul/2012

Title: TREATMENT OF ERECTILE DYSFUNCTION USING PLATELET-RICH PLASMA

Applicant/Assignee: BIOMET BIOLOGICS, LLC

Application No.: 13/006149   Filing Date: 13/Jan/2011

Abstract:

Methods, apparatus, and compositions related to a method of treating erectile dysfunction in a subject, the method comprising administering a composition comprising platelet-rich plasma at or proximate to ischemic tissue comprising the corpora cavernosa or corpus spongiosum.

Priority:

Inventor: SWIFT MATTHEW [US]


Application No.: US20120184516A1  Published: 19/Jul/2012

Title: sGC Stimulators

Applicant/Assignee:

Application No.: 13/174676   Filing Date: 30/Jun/2011

Abstract:

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Priority: US2010-360236P Applic. Date: 2010-06-30; US2010-406845P Applic. Date: 2010-10-26; US201161474563P Applic. Date: 2011-04-12

Inventor: KIM CHARLES [US]; NAKAI TAKASHI [US]; LEE THOMAS WAI-HO [US]; MOORE JOEL [US]; PERL NICHOLAS ROBERT [US]; ROHDE JASON [US]; IYENGAR RAJESH R [US]; MERMERIAN ARA [US]


Application No.: US20120189711A1  Published: 26/Jul/2012

Title: Modular Extracorporeal Systems and Methods for Treating Blood-Borne Diseases

Applicant/Assignee: SOMERSET GROUP ENTERPRISES, INC

Application No.: 13/346321   Filing Date: 09/Jan/2012

Abstract:

Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.

Priority: US201161430634P Applic. Date: 2011-01-07

Inventor: GREENBERG DAVID G [US]; PURITZ SCOTT [US]; KOUTCHMA TATIANA [US]; WALTERSPIEL JUAN N [US]


Application No.: US20120196806A1  Published: 02/Aug/2012

Title: ANTICOAGULANT AND COMPOSITION FOR PREVENTING THROMBUS CONTAINING POLY-GAMMA-GLUTAMIC ACID

Applicant/Assignee: BIOLEADERS CORPORATION

Application No.: 13/444324   Filing Date: 11/Apr/2012

Abstract:

The present invention relates to an anticoagulant and a composition for preventing thrombus formation, which contain poly-gamma-glutamic acid (PGA) as an active ingredient. The inventive PGA is a water-soluble, anionic, biodegradable and edible amino acid polymer material, which has an anticoagulant effect of preventing thrombi from being accumulated in blood vessels, shows an excellent sustained-release effect and is harmless to the human body. Thus, it is useful as a high-value-added anticoagulant and a food or beverage composition for preventing thrombus formation.

Priority: KR20050133055 Applic. Date: 2005-12-29; US2008-159561 Applic. Date: 2008-10-30; WO2006KR05685 Applic. Date: 2006-12-22

Inventor: SUNG MOON-HEE [KR]; PARK CHUNG [KR]; HONG SEUNG-PYO [KR]; POO HARYOUNG [KR]; KIM TAE-WOO [KR]


Application No.: US20120197174A1  Published: 02/Aug/2012

Title: Metabolic Detoxification System and Method

Applicant/Assignee: VITAL THERAPIES, INC

Application No.: 13/361812   Filing Date: 30/Jan/2012

Abstract:

An extracorporeal filtration and detoxification system and method generally comprise separating ultrafiltrate from cellular components of blood, treating the ultrafiltrate independently of the cellular components in a recirculation circuit, recombining treated ultrafiltrate and the cellular components, and returning whole blood to the patient. A recirculation circuit generally comprises an active cartridge including active cells operative to effectuate a selected treatment

in some embodiments, the active cells are the C3A cell line.

Priority: US2005-064566 Applic. Date: 2005-02-23; US2004-565888P Applic. Date: 2004-04-27

Inventor: BROTHERTON JOHN D [US]; HE DAR [US]


Application No.: US20120201787A1  Published: 09/Aug/2012

Title: TREATMENT OF SPINAL CORD INJURY AND TRAUMATIC BRAIN INJURY USING AMNION DERIVED ADHERENT CELLS

Applicant/Assignee:

Application No.: 13/327289   Filing Date: 15/Dec/2011

Abstract:

Provided herein are methods of treating spinal cord and traumatic brain injuries using cells from amnion, and populations of such cells, referred to herein as "amnion derived adherent cells" ("AMDACs").

Priority: US201061424596P Applic. Date: 2010-12-17

Inventor: ABBOT STEWART [US]; EDINGER JAMES W [US]; FRANCKI ALEKSANDAR [US]; JANKOVIC VLADIMIR [US]; KAPLUNOVSKY ALEKSANDR [US]; LABAZZO KRISTEN [US]; LAW ERIC [US]; LIANG BITAO [US]


Application No.: US20120201816A1  Published: 09/Aug/2012

Title: LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 13/444999   Filing Date: 12/Apr/2012

Abstract:

The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4 I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US201113101536 Applic. Date: 2011-05-05; US2010-691895 Applic. Date: 2010-01-22; US2009-401401 Applic. Date: 2009-03-10; US2007-955678 Applic. Date: 2007-12-13; US2005-198801 Applic. Date: 2005-08-05; US2004-850587 Applic. Date: 2004-05-20; US2002-245122 Applic. Date: 2002-09-17; US2002-402317P Applic. Date: 2002-08-09; US2001-324165P Applic. Date: 2001-09-21

Inventor: PINTO DONALD J P [US]; QUAN MIMI L [US]; ORWAT MICHAEL J [US]; LI YUN-LONG [US]; HAN WEI [US]; QIAO JENNIFER X [US]; LAM PATRICK Y S [US]; KOCH STEPHANIE L [US]


Application No.: US20120201872A1  Published: 09/Aug/2012

Title: LIPOSOMES COMPRISING A CALCIUM PHOSPHATE-CONTAINING PRECIPITATE

Applicant/Assignee: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Application No.: 13/388538   Filing Date: 03/Aug/2010

Abstract:

Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject.

Priority: US2009-230783P Applic. Date: 2009-08-03; US2009-258028P Applic. Date: 2009-11-04; WO2010US44209 Applic. Date: 2010-08-03

Inventor: HUANG LEAF [US]; LI JUN [US]


Application No.: US20120203201A1  Published: 09/Aug/2012

Title: Methods for Preparing a Heat Exchange Catheter System and for Heating and/or Cooling a Subject's Body

Applicant/Assignee: ZOLL CIRCULATION INC

Application No.: 13/367956   Filing Date: 07/Feb/2012

Abstract:

Closed loop heat exchange catheter systems and methods for preparing and using such systems wherein a reservoir or fluid bag is connected to the catheter system and used for at least priming of the system with a heat exchange fluid.

Priority: US2010-853864 Applic. Date: 2010-08-10; US2007-931463 Applic. Date: 2007-10-31; US2007-724075 Applic. Date: 2007-03-13; US2003-626007 Applic. Date: 2003-07-24; US1998-138830 Applic. Date: 1998-08-24

Inventor: GINSBURG ROBERT [US]; GINSBURG ARLENE S [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]


Application No.: US20120209321A1  Published: 16/Aug/2012

Title: APPARATUS AND METHODS FOR DELIVERING HEMOSTATIC MATERIALS FOR BLOOD VESSEL CLOSURE

Applicant/Assignee: CARDIVA MEDICAL, INC

Application No.: 13/452656   Filing Date: 20/Apr/2012

Abstract:

Apparatus for sealing a vascular wall penetration disposed at the end of the tissue tract comprises a shaft, an occlusion element, a hemostatic implant, and a protective sleeve. The apparatus is deployed through the tissue tract with the occlusion element temporarily occluding the vascular wall penetration and inhibiting backbleeding therethrough. The hemostatic implant, which will typically be a biodegradable polymer such as collagen carrying an anti-proliferative agent or coagulation promoter, will then be deployed from the sealing apparatus and left in place to enhance closure of the vascular wall penetration with minimum scarring. The implant may be radiopaque to allow observation before release.

Priority: US2009-492779 Applic. Date: 2009-06-26; US2007-772718 Applic. Date: 2007-07-02; US2005-302951 Applic. Date: 2005-12-13; US2008-077104P Applic. Date: 2008-06-30

Inventor: YASSINZADEH ZIA [US]; PELAYO DELFIN [US]


Application No.: US20120215156A1  Published: 23/Aug/2012

Title: SELECTIVE RESONANCE OF BODILY AGENTS

Applicant/Assignee: SEARETE LLC

Application No.: 13/457993   Filing Date: 27/Apr/2012

Abstract:

Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.

Priority: US2005-186633 Applic. Date: 2005-07-21; US2006-441786 Applic. Date: 2006-05-26; US2005-186635 Applic. Date: 2005-07-21; US2008-313418 Applic. Date: 2008-11-19; US2005-186632 Applic. Date: 2005-07-21; US2008-313411 Applic. Date: 2008-11-19; US2005-186394 Applic. Date: 2005-07-21; US201113134267 Applic. Date: 2011-06-03; US2005-186634 Applic. Date: 2005-07-21; US2008-313419 Applic. Date: 2008-11-19; US2005-186631 Applic. Date: 2005-07-21; US2008-313417 Applic. Date: 2008-11-19; US2005-260467 Applic. Date: 2005-10-26; US2007-904044 Applic. Date: 2007-09-24

Inventor: ISHIKAWA MURIEL Y [US]; JUNG EDWARD K Y [US]; LEUTHARDT ERIC C [US]; MYHRVOLD NATHAN P [US]; WOOD JR LOWELL L [US]


Application No.: US20120220617A1  Published: 30/Aug/2012

Title: Fluorescent Perylene Derivatives for Direct Detection of Heparin

Applicant/Assignee:

Application No.: 13/390799   Filing Date: 19/Aug/2010

Abstract:

The invention relates to a perylene diimide derivative and to an in vitro method for preparing the same. In addition, the invention relates to a method for detecting heparin in a sample using perylene diimide derivatives, wherein the interaction of the perylene diimide derivative with heparin modulates the intensity of the fluorescent signal of the mixture compared to the solution. The invention also comprises a diagnostic kit for detecting heparin in a sample in vitro, comprising the perylene diimide derivative, as well as the use of the perylene diimide derivative for neutralizing the anticoagulant activity of heparin.

Priority: WO2010EP62118 Applic. Date: 2010-08-19; EP20090168292 Applic. Date: 2009-08-20

Inventor: KRAEMER ROLAND [DE]; SZELKE HELGA [CH]; HARENBERG JOB [DE]; POECK ARMIN [DE]


Application No.: US20120225116A1  Published: 06/Sep/2012

Title: BIODEGRADABLE POLYPHOSPHAZENES CONTAINING PYRROLIDONE SIDE GROUPS

Applicant/Assignee:

Application No.: 13/470453   Filing Date: 14/May/2012

Abstract:

Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.

Priority: US2010-803908 Applic. Date: 2010-07-09; US2007-974528 Applic. Date: 2007-10-12; US2003-715787 Applic. Date: 2003-11-18

Inventor: ANDRIANOV ALEXANDER K [US]; ROBERTS BRYAN E [US]


Application No.: US20120225419A1  Published: 06/Sep/2012

Title: METHODS AND SYSTEMS FOR PROVIDING RED BLOOD CELL PRODUCTS WITH REDUCED PLASMA

Applicant/Assignee: FENWAL, INC

Application No.: 13/502934   Filing Date: 23/Sep/2010

Abstract:

Methods and systems for processing and conditioning red blood cells are disclosed. The methods and systems may be used to make a readily transfusible red blood cell product with reduced plasma. In general, the plasma content of the supernatant of the red blood cell product is no greater than about 15%. The red blood cell products are prepared using the disclosed methods and systems remain transfusible for up to 42 days.

Priority: US2009-254550P Applic. Date: 2009-10-23; WO2010US50036 Applic. Date: 2010-09-23

Inventor: MIN KYUNGYOON [US]; RADWANSKI KATHERINE [US]


Application No.: US20120231485A1  Published: 13/Sep/2012

Title: METHOD FOR MONITORING ANTICOAGULANT THERAPY

Applicant/Assignee:

Application No.: 13/414112   Filing Date: 07/Mar/2012

Abstract:

A method of measuring the combined activity of both and only coagulation factors II and X for the purpose of monitoring anticoagulant therapy, and kits for using the method. The method involves mixing of test plasma from a human to be tested with specially prepared plasma deficient in both and only coagulation factors II and X but with normal levels of other factors (referred to herein as Fiix-deficient plasma or Fiix plasma), in order to correct for any possible deficiency in other coagulation factors than FII and FX in the test sample. By adding a coagulation reagent and calcium, the generation of thrombin or fibrin can be measured. Kits of the invention comprise a coagulation reagent, calcium and specially made plasma that is deficient in both and only factor II and factor FX.

Priority: IS20110050010 Applic. Date: 2011-03-08

Inventor: OENUNDARSON PALL TORFI [IS]; GUDMUNDSDOTTIR BRYNJA R [IS]


Application No.: US20120231503A1  Published: 13/Sep/2012

Title: Gene Expression Technique

Applicant/Assignee: NOVOZYMES BIOPHARMA DK A/S

Application No.: 13/474317   Filing Date: 17/May/2012

Abstract:

The present disclosure relates to a method for producing heterologous protein including: (c) providing a host cell comprising a 2 [mu]m-family plasmid, the plasmid comprising a gene encoding a protein comprising the sequence of a chaperone protein and a gene encoding a heterologous protein

(d) culturing the host cell in a culture medium under conditions that allow the expression of the gene encoding the chaperone protein and the gene encoding a heterologous protein

(e) purifying the thus expressed heterologous protein from the cultured host cell or the culture medium.

Priority: GB20030029681 Applic. Date: 2003-12-23; US2007-584424 Applic. Date: 2007-04-10; WO2004GB05462 Applic. Date: 2004-12-23

Inventor: SLEEP DARRELL [GB]; SHUTTLEWORTH GILLIAN [GB]; FINNIS CHRISTOPHER JOHN ARTHUR [GB]


Application No.: US20120231505A1  Published: 13/Sep/2012

Title: Gene Expression Technique

Applicant/Assignee: NOVOZYMES BIOPHARMA DK A/S

Application No.: 13/474313   Filing Date: 17/May/2012

Abstract:

The present invention provides a method for producing a desired protein (such as a desired heterologous protein) comprising: (a) providing a host cell comprising a first recombinant gene encoding a protein comprising the sequence of a first chaperone protein, a second recombinant gene encoding a protein comprising the sequence of a second chaperone protein and a third gene, such as a third recombinant gene, encoding a desired protein (such as a desired heterologous protein), wherein the first and second chaperones are different

and (b) culturing the host cell in a culture medium to obtain expression of the first, second and third genes.

Priority: WO2004GB05462 Applic. Date: 2004-12-23; WO2004GB05435 Applic. Date: 2004-12-23; WO2005GB05085 Applic. Date: 2005-12-23; US2007-722539 Applic. Date: 2007-06-22; GB20030029722 Applic. Date: 2003-12-23; GB20030029681 Applic. Date: 2003-12-23

Inventor: FINNIS CHRISTOPHER JOHN ARTHUR [GB]; SLEEP DARRELL [GB]; SHUTTLEWORTH GILLIAN [GB]


Application No.: US20120232014A1  Published: 13/Sep/2012

Title: ANTITHROMBOTIC COMPOUNDS

Applicant/Assignee: IMPERIAL INNOVATIONS LIMITED, KING'S COLLEGE LONDON

Application No.: 13/394177   Filing Date: 06/Sep/2010

Abstract:

A soluble compound for preventing or reducing blood coagulation comprising an antithrombotic agent and a membrane binding element, wherein the antithrombotic agent has a weight of less than about 5,000 daltons. Also disclosed is a soluble compound for preventing or reducing blood coagulation comprising an anticoagulant joined to a membrane binding element via a joining element, wherein the joining element between the anticoagulant and the membrane binding element is less than about 10,000 daltons in weight. These compounds can be used in therapy and, in particular, in preventing or reducing blood coagulation. As a result, a method of treatment is provided comprising administering an effective amount of the compounds to a subject to prevent or reduce blood coagulation as well as a method of perfusing an organ, tissue or cell comprising contacting the compounds with the organ, tissue or cell to prevent or reduce blood coagulation. Also disclosed is an organ, tissue or cell which has been perfused with the compounds.

Priority: GB20090015519 Applic. Date: 2009-09-04; WO2010GB51478 Applic. Date: 2010-09-06

Inventor: SMITH RICHARD ANTHONY GODWIN [GB]; SACKS STEVEN HOWARD [GB]; DORLING ANTHONY [GB]


Application No.: US20120232458A1  Published: 13/Sep/2012

Title: IMPLANTABLE SYSTEMS AND METHODS FOR REMOVING SPECIFIC IMPURITIES FROM FLUIDS SUCH AS BLOOD

Applicant/Assignee:

Application No.: 13/044147   Filing Date: 09/Mar/2011

Abstract:

Systems and methods utilize semipermeable nanotubes in conjunction with application of controlled electrical potentials across semipermeable nanotube walls allow selective transport of charged impurities (e.g., charged impurities, ions, etc.) from a fluid into these nanotubes. Impurities collected in these nanotubes can then be removed from the fluid, (e.g., blood) as a waste stream. A collection of semipermeable nanotubes each carrying a waste stream can be aggregated and merged into a ureter for excretion thereby providing an artificial kidney system. Sensors that detect/measure various impurities may be included in the system to feed information to a microprocessor to inform on concentrations of impurities, and thereby control electrical potentials applied to the system.

Priority:

Inventor: HERSCHMAN ZVI [US]


Application No.: US20120238026A1  Published: 20/Sep/2012

Title: BLOOD COAGULATION SYSTEM ANALYZING METHOD AND BLOOD COAGULATION SYSTEM ANALYZING DEVICE

Applicant/Assignee: SONY CORPORATION

Application No.: 13/403652   Filing Date: 23/Feb/2012

Abstract:

A blood coagulation system analyzing method includes acquiring information relating to the coagulability of blood based on a change generated in a complex permittivity spectrum measured in a coagulation process of the blood due to addition of a substance that activates or inactivates platelets to the blood.

Priority: JP20110058810 Applic. Date: 2011-03-17

Inventor: HAYASHI YOSHIHITO [JP]; BRUN MARCAURELE [JP]; OMORI SHINJI [JP]; KATSUMOTO YOICHI [JP]; SATO KAZUMASA [JP]


Application No.: US20120239001A1  Published: 20/Sep/2012

Title: LOADING AND RELEASE OF WATER-INSOLUBLE DRUGS

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 13/483850   Filing Date: 30/May/2012

Abstract:

A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coating is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.

Priority: US201113085623 Applic. Date: 2011-04-13; US2007-833717 Applic. Date: 2007-08-03; US2005-188850 Applic. Date: 2005-07-26; US2001-978763 Applic. Date: 2001-10-18; US1998-172026 Applic. Date: 1998-10-14; US1998-133603 Applic. Date: 1998-08-13; US1997-910136 Applic. Date: 1997-08-13

Inventor: BARRY JAMES J [US]; PALASIS MARIA [US]


Application No.: US20120252765A1  Published: 04/Oct/2012

Title: USE OF IRBESARTAN FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OF HOSPITALIZATION FOR HEART FAILURE

Applicant/Assignee: SANOFI

Application No.: 13/405896   Filing Date: 27/Feb/2012

Abstract:

Use of irbesartan or one of its pharmaceutically acceptable salts for the preparation of a medicament for the prevention of hospitalization for heart failure.

Priority: FR20090004132 Applic. Date: 2009-08-31; WO2010IB53904 Applic. Date: 2010-08-31

Inventor: MARCHESE CATHERINE [FR]; GAUDIN CHRISTOPHE [FR]


Application No.: US20120258095A1  Published: 11/Oct/2012

Title: Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

Applicant/Assignee: OMEROS CORPORATION, UNIVERSITY OF LEICESTER

Application No.: 13/441827   Filing Date: 06/Apr/2012

Abstract:

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Priority: US201161473698P Applic. Date: 2011-04-08

Inventor: DEMOPULOS GREGORY A [US]; DUDLER THOMAS [US]; SCHWAEBLE HANS-WILHELM [GB]


Application No.: US20120258459A1  Published: 11/Oct/2012

Title: SYSTEM AND METHOD FOR PARTICLE FILTRATION

Applicant/Assignee: CYTOVERA INC

Application No.: 13/518514   Filing Date: 22/Dec/2010

Abstract:

Embodiments of the present disclosure feature a filtration system comprising a filtration module for particle filtration and methods of using the device for the isolation of particles (e.g., viable cells). Advantageously, embodiments of the device provide for the high throughput filtration of large volumes of sample while preserving cell viability and. providing high yields.

Priority: US2010-294611P Applic. Date: 2010-01-13; US2009-289730P Applic. Date: 2009-12-23; WO2010US61866 Applic. Date: 2010-12-22

Inventor: HUANG LOTIEN [US]


Application No.: US20120259007A1  Published: 11/Oct/2012

Title: ANTICOAGULANT COMPOUNDS AND THEIR USE

Applicant/Assignee: HAOMA MEDICA LIMITED

Application No.: 13/518618   Filing Date: 22/Dec/2010

Abstract:

According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use as an anticoagulant.

Priority: WO2010GB52194 Applic. Date: 2010-12-22; GB20090022510 Applic. Date: 2009-12-23

Inventor: HODGES STEPHEN [GB]; SOPER ROBIN [GB]


Application No.: US20120259022A1  Published: 11/Oct/2012

Title: PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS

Applicant/Assignee:

Application No.: 13/527536   Filing Date: 19/Jun/2012

Abstract:

A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.

Priority: US201113208305 Applic. Date: 2011-08-11; US2000-742785 Applic. Date: 2000-12-20; US1999-171841P Applic. Date: 1999-12-23

Inventor: CURATOLO WILLIAM J [US]; SHANKER RAVI M [US]; BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; NIGHTINGALE JAMES A S [US]; LORENZ DOUGLAS A [US]


Application No.: US20120259315A1  Published: 11/Oct/2012

Title: DOUBLE BALLOON CATHETER AND METHODS FOR HOMOGENEOUS DRUG DELIVERY USING THE SAME

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 13/446400   Filing Date: 13/Apr/2012

Abstract:

The present disclosure is directed to a catheter for site-specific delivery of a therapeutic agent to a blood vessel of a patient. The catheter further includes an elongated shaft having at least one inner lumen, a distal end and a proximal end and proximal and distal vessel-conforming balloons where each is separately positionable and inflatable, and when inflated, substantially restricts blood flow in the vessel and creates a treatment window of a defined but variable length for delivery of the therapeutic agent. The catheter optionally includes at least one marker band adjacent to the proximal balloon and at least one marker band adjacent to the distal balloon. At least one lateral aperture positioned in the window is in fluid communication with a drug delivery conduit located within either the inner shaft or the outer shaft to provide a homogeneous concentration of the therapeutic agent to the window.

Priority: US2009-564771 Applic. Date: 2009-09-22; US2008-099127P Applic. Date: 2008-09-22

Inventor: HATTANGADI NEIL [US]; LERNER DANIEL [US]; OLIVERA RYAN [US]


Application No.: US20120264692A1  Published: 18/Oct/2012

Title: GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF

Applicant/Assignee: LEIDEN UNIVERSITY MEDICAL CENTER (LUMC) ACTING ONBEHALF OF ACADEMIC HOSPITAL LEIDEN (AZL), CELERA CORPORATION

Application No.: 13/270936   Filing Date: 11/Oct/2011

Abstract:

The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Priority: US2009-403552 Applic. Date: 2009-03-13; US2008-069687P Applic. Date: 2008-03-13

Inventor: BARE LANCE [US]; DEVLIN JAMES J [US]; ROSENDAAL FRITS R [NL]; REITSMA PIETER H [NL]; BEZEMER IRENE D [NL]


Application No.: US20120265116A1  Published: 18/Oct/2012

Title: SYSTEM AND METHOD FOR DELIVERY OF REGIONAL CITRATE ANTICOAGULATION TO EXTRACORPOREAL BLOOD CIRCUITS

Applicant/Assignee: HENRY FORD HEALTH SYSTEM

Application No.: 13/528078   Filing Date: 20/Jun/2012

Abstract:

The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Priority: US2008-280450 Applic. Date: 2008-12-16; WO2007US62589 Applic. Date: 2007-02-22; US2006-775729P Applic. Date: 2006-02-22; US2006-775728P Applic. Date: 2006-02-22; US2006-791055P Applic. Date: 2006-04-11; US2006-790882P Applic. Date: 2006-04-11; US2006-845646P Applic. Date: 2006-09-19

Inventor: SZAMOSFALVI BALAZS [US]; FRINAK STANLEY [US]; YEE JERRY [US]


Application No.: US20120265123A1  Published: 18/Oct/2012

Title: Central Nervous System Drain

Applicant/Assignee: NEUROVENTION, LLC

Application No.: 13/535084   Filing Date: 27/Jun/2012

Abstract:

The invention provides a method and apparatus for maintaining central nervous system drain patency. Ultrasound energy delivered through the drain dissolves the hemorrhage and debris occluding the drain lumen and ports.

Priority: US2008-008611 Applic. Date: 2008-01-11; US2006-418849 Applic. Date: 2006-05-05

Inventor: KHANNA ROHIT [US]


Application No.: US20120270789A1  Published: 25/Oct/2012

Title: TREATMENT OF COAGULOPATHY WITH HYPERFIBRINOLYSIS

Applicant/Assignee: PAION DEUTSCHLAND GMBH

Application No.: 13/377497   Filing Date: 12/Jun/2009

Abstract:

The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogs exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed.

Priority: WO2009EP04218 Applic. Date: 2009-06-12

Inventor: PETERSEN KARL-UWE [DE]; NESHEIM MICHAEL ERNEST [CA]; NESHEIM DANIEL [CA]; FOLEY JONATHAN HERBERT [CA]


Application No.: US20120271010A1  Published: 25/Oct/2012

Title: HYDROPHILIC POLYMER COMPOUND HAVING ANTICOAGULATION EFFECT

Applicant/Assignee: TORAY INDUSTRIES, INC

Application No.: 13/517175   Filing Date: 22/Dec/2010

Abstract:

A hydrophilic polymer compound includes a polymer compound which inhibits platelet adhesion, and a compound that inhibits blood coagulation reaction, bound to the polymer compound.

Priority: JP20090292146 Applic. Date: 2009-12-24; WO2010JP73092 Applic. Date: 2010-12-22

Inventor: SAKAGUCHI HIROKAZU [JP]; SAKAGUCHI YUKA [JP]; TANAHASHI KAZUHIRO [JP]


Application No.: US20120271223A1  Published: 25/Oct/2012

Title: Central Nervous System Drain

Applicant/Assignee: NEUROVENTION, LLC

Application No.: 13/535072   Filing Date: 27/Jun/2012

Abstract:

The invention provides a method and apparatus for maintaining central nervous system drain patency. Ultrasound energy delivered through the drain dissolves the hemorrhage and debris occluding the drain lumen and ports.

Priority: US2008-008611 Applic. Date: 2008-01-11; US2006-418849 Applic. Date: 2006-05-05

Inventor: KHANNA ROHIT [US]


Application No.: US20120275955A1  Published: 01/Nov/2012

Title: PLASMA OR SERUM PRODUCTION AND REMOVAL OF FLUIDS UNDER REDUCED PRESSURE

Applicant/Assignee: SEVENTH SENSE BIOSYSTEMS, INC

Application No.: 13/456505   Filing Date: 26/Apr/2012

Abstract:

In some embodiments, the present invention generally relates to the separation of blood within a device to form plasma or serum. In some embodiments, the present invention generally relates to the removal of fluids, such as blood, contained within a device. For example, a device may be applied to the skin of a subject to receive blood from the subject and pass the blood through a separation membrane, which separates the blood into plasma and a portion concentrated in blood cells. As another example, blood or plasma may be allowed to clot within the device and serum (the unclotted portion of the blood) may be withdrawn from the device. The device may contain, in some cases, a vacuum source such as a pre-packaged vacuum to facilitate receiving of blood and/or passage of the blood through the separation membrane to produce plasma or serum.

Priority: US201161480941P Applic. Date: 2011-04-29; US201161549437P Applic. Date: 2011-10-20

Inventor: HAGHGOOIE RAMIN [US]; CHICKERING III DONALD E [US]; DAVIS SHAWN [US]; MICHELMAN MARK [US]; BERNSTEIN HOWARD [US]; HORTON KRISTIN [US]


Application No.: US20120277269A1  Published: 01/Nov/2012

Title: METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 13/543080   Filing Date: 06/Jul/2012

Abstract:

A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

Priority: US2010-817369 Applic. Date: 2010-06-17; WO2009EP64874 Applic. Date: 2009-11-10; US2008-113413P Applic. Date: 2008-11-11; US2009-237559P Applic. Date: 2009-08-27

Inventor: REILLY PAUL ANTHONY [US]


Application No.: US20120277726A1  Published: 01/Nov/2012

Title: DRUG-ELUTING INSERTABLE MEDICAL DEVICE FOR TREATING ACUTE MYOCARDIAL INFARCTION, THROMBUS CONTAINING LESIONS AND SAPHENOUS-VEIN GRAFT LESIONS

Applicant/Assignee: ENVISION SCIENTIFIC PRIVATE LIMITED

Application No.: 13/124124   Filing Date: 06/Jan/2011

Abstract:

A method for delivering at least one drug at a target site in a blood vessel for treating at least one of an acute myocardial infarction, a thrombus containing lesion and a saphenous-vein graft lesion is disclosed. The method includes delivering nano-carriers at the target site. The nano-carriers include one or more drugs encapsulated with a first biological agent. The nano-carriers further include a second biological agent in contact with one or more of the first biological agent and the one or more drugs. The first biological agent and the second biological agent have a first dissolution rate and a second dissolution rate respectively. The first dissolution rate is different from the second dissolution rate. The one or more drugs are released at the target site from the nano-carriers at a first release rate and a second release rate in response to dissolution of the first biological agent and the second biological agent, respectively.

Priority: IN2010MU00177 Applic. Date: 2010-01-22; WO2011IN00007 Applic. Date: 2011-01-06

Inventor: DOSHI MANISH [IN]; SHERDIWALA DIVYESH [IN]; SOJITRA PRAKASH [IN]


Application No.: US20120282187A1  Published: 08/Nov/2012

Title: METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED SAFETY PROFILE OVER CONVENTIONAL WARFARIN THERAPY

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 13/548423   Filing Date: 13/Jul/2012

Abstract:

A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

Priority: US2010-817347 Applic. Date: 2010-06-17; WO2009EP64873 Applic. Date: 2009-11-10; US2009-237552P Applic. Date: 2009-08-27; US2008-113404P Applic. Date: 2008-11-11

Inventor: REILLY PAUL ANTHONY [US]


Application No.: US20120282240A1  Published: 08/Nov/2012

Title: THROMBIN ISOLATED FROM BLOOD AND BLOOD FRACTIONS

Applicant/Assignee: BIOMET BIOLOGICS, LLC

Application No.: 13/099087   Filing Date: 02/May/2011

Abstract:

Methods, apparatus, and compositions related to generating and using thrombin. Methods include preparing a solution comprising thrombin by precipitating fibrinogen from a liquid comprising whole blood or a blood fraction. Precipitated fibrinogen is removed from the liquid to form a post-precipitation liquid that is incubated with calcium and a plurality of beads to form a clot. A solution comprising thrombin is separated from the clot. Thrombin prepared thereby can be used as a tissue sealant and in methods of applying a tissue sealant to subject, including application of an autologous tissue sealant.

Priority:

Inventor: OVERHOLSER HILLARY [US]; WOODELL-MAY JENNIFER [US]


Application No.: US20120283562A1  Published: 08/Nov/2012

Title: In Situ Modification of Therapeutic Agents Using Heat Exchange Catheter System

Applicant/Assignee: ZOLL CIRCULATION INC

Application No.: 13/367910   Filing Date: 07/Feb/2012

Abstract:

Closed loop heat exchange catheter systems and methods for preparing and using such systems wherein a reservoir or fluid bag is connected to the catheter system and used for at least priming of the system with a heat exchange fluid.

Priority: US2010-853864 Applic. Date: 2010-08-10; US2007-931463 Applic. Date: 2007-10-31; US2007-724075 Applic. Date: 2007-03-13; US2003-626007 Applic. Date: 2003-07-24; US1998-138830 Applic. Date: 1998-08-24

Inventor: GINSBURG ROBERT [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]; GINSBURG ARLENE S [US]


Application No.: US20120295246A1  Published: 22/Nov/2012

Title: BLOOD CELL SORTING METHODS AND SYSTEMS

Applicant/Assignee: THE GENERAL HOSPITAL CORPORATION

Application No.: 13/481237   Filing Date: 25/May/2012

Abstract:

The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples.

Priority: US2011-987575 Applic. Date: 2011-01-10; US2006-646985 Applic. Date: 2006-12-28; US2005-754426P Applic. Date: 2005-12-28

Inventor: FAUSTMAN DENISE L [US]; BURGER DOUGLAS E [US]


Application No.: US20120295290A1  Published: 22/Nov/2012

Title: MAGNETIC BEADS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 13/559753   Filing Date: 27/Jul/2012

Abstract:

Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.

Priority: US2010-815132 Applic. Date: 2010-06-14

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; DAVIS GRAHAM [US]


Application No.: US20120295359A1  Published: 22/Nov/2012

Title: AUTOMATED METHOD AND APPARATUS FOR DETECTING ERRONEOUS SAMPLE COLLECTION IN CLINICAL ASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 13/565930   Filing Date: 03/Aug/2012

Abstract:

An automatic method for identifying biological samples that are collected using the wrong blood preservative for subsequent analytical testing. The method also provides for identification and/or suppression of certain analytical test results that are substantially or partly adversely affected. The invention is particularly suited for use in point-of-care medical diagnostic testing.

Priority: US2008-339886 Applic. Date: 2008-12-19; US2007-015582P Applic. Date: 2007-12-20

Inventor: BROUWER ERIC [CA]; TIRINATO JODY ANN [US]; ZELIN MICHAEL P [US]


Application No.: US20120295988A1  Published: 22/Nov/2012

Title: Pharmaceutical Compositions of Dispersions of Amorphous Drugs Mixed with Polymers

Applicant/Assignee:

Application No.: 13/563536   Filing Date: 31/Jul/2012

Abstract:

A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.

Priority: US2008-217700 Applic. Date: 2008-07-08; US2002-175640 Applic. Date: 2002-06-19; US2001-300261P Applic. Date: 2001-06-22

Inventor: BABCOCK WALTER C [US]; CURATOLO WILLIAM J [US]; FRIESEN DWAYNE T [US]; KETNER RODNEY J [US]; LO JULIAN B [US]; NIGHTINGALE JAMES A S [US]; SHANKER RAVI M [US]; WEST JAMES B [US]


Application No.: US20120301458A1  Published: 29/Nov/2012

Title: CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/844017   Filing Date: 27/Jul/2010

Abstract:

The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof

Priority: US2009-228913P Applic. Date: 2009-07-27

Inventor: RAO TADIMETI [US]; ZHANG CHENGZHI [US]


Application No.: US20120302640A1  Published: 29/Nov/2012

Title: ORAL FORMULATIONS

Applicant/Assignee:

Application No.: 13/524646   Filing Date: 15/Jun/2012

Abstract:

The invention relates to a composition, in the form of a gel, comprising tranexamic acid for topical oral application to a tooth extraction site either before, during or after the tooth extraction to control dental bleeding, to treat or prevent alveolar osteitis, or to produce or maintain a blood clot. The composition may comprise additional components such as chlorhexidine, methyl cellulose, a sweetener, a flavouring agent (e.g. mint), and a preservative (e.g. potassium sorbate).

Priority: NZ20090582165 Applic. Date: 2009-12-17; WO2010NZ00256 Applic. Date: 2010-12-17

Inventor: MACALISTER DON [NZ]


Application No.: US20120329586A1  Published: 27/Dec/2012

Title: Slingblade Broad-head Delivery System

Applicant/Assignee:

Application No.: 13/167619   Filing Date: 23/Jun/2011

Abstract:

A bow hunting broad-head system having a mechanical cutter which opens after impact. The broad-head flies to its destination with minimal drag and having good balance. After impact, the tip opens to a larger diameter creating a devastating wound and releases the payload inside the animal.

Priority:

Inventor: PEETZ JASON [US]; SCHROEDER MARK [US]

...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
US Patent Applications published in 2012
US Patent Applications published in 2011
Provisional Patents in Blood Anticlot Technology, Medications and
Medical Devices Published in 2012